The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins
Open accessAbstract
Thiazolidinedione (TZD) insulin sensitizers have the potential to effectively treat a number of human diseases, however the currently available agents have dose-limiting side effects that are mediated via activation of the transcription factor PPARγ. We have recently shown PPARγ-independent actions of TZD insulin sensitizers, but the molecular target of these molecules remained to be identified. Here we use a photo-catalyzable drug analog probe and mass spectrometry-based proteomics to identify a previously uncharacterized mitochondrial complex that specifically recognizes TZDs. These studies identify two well-conserved proteins previously known as brain protein 44 (BRP44) and BRP44 Like (BRP44L), which recently have been renamed Mpc2 and Mpc1 to signify their function as a mitochondrial pyruvate carrier complex. Knockdown of Mpc1 or Mpc2 in Drosophila melanogaster or pre-incubation with UK5099, an inhibitor of pyruvate transport, blocks the crosslinking of mitochondrial membranes by the TZD probe. Knockdown of these proteins in Drosophila also led to increased hemolymph glucose and blocked drug action. In isolated brown adipose tissue (BAT) cells, MSDC-0602, a PPARγ-sparing TZD, altered the incorporation of (13)C-labeled carbon from glucose into acetyl CoA. These results identify Mpc1 and Mpc2 as components of the mitochondrial target of TZDs (mTOT) and suggest that understanding the modulation of this complex, which appears to regulate pyruvate entry into the mitochondria, may provide a viable target for insulin sensitizing pharmacology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Selective crosslinking with photo affinity probe. (A) Mitochondrial membranes (20 µg) from rat liver were incubated with the iodinated (125I) photo-probe (MSDC-1101) in the absence of any competing compound (lane 1); in the presence of 25 µM MSDC-0160 (lane 2); in the presence of 25 µM MSDC-0602 (lane 3); or in the presence of 25 µM MSDC-1473 (lane 4). Following exposure to UV light, samples were separated on one dimensional SDS-PAGE and the dried gel was exposed to X-ray film. (B) Active TZDs, but not MSDC-1473, produce a dose-dependent increase in UCP1 as detected on Western blots from mouse BAT progenitor cells. The abscissa shows drug concentration (µM). The inset on the top of this figure shows a representative Western blot of the increase in UCP1 protein in cells treated with an active TZD (pioglitazone). The data below the blot show the dose dependent increases observed in a representative experiment from a scan of the Western blots (arbitrary units, Mean and SE; N = 3). (C) Liver mitochondrial fractions from wild type or mitoNEET null mice [11] were crosslinked as in A without (−) or with (+) 25 µM MSDC-0160. The top figure is the resulting autoradiogram and the bottom is the Western blot for mitoNEET. (D) Mouse liver mitochondria were fractionated to generate fractions for outer membrane (OM), inter membrane space (IMS), inner membrane (IMM), and matrix. Total protein (10 µg) from each fraction was crosslinked as in A. The autoradiogram is shown at the top and a stain for total protein for the same 4 mitochondrial subfractions is shown below.](/paper-figures/c52128d21b004749b5d3eea8077be2ae/identification-of-a-mitochondrial-target-of-thiazolidinedione-insulin-figure-1.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, the MPC has emerged as an unanticipated target of thiazolidinediones (Colca et al., 2013; Divakaruni et al., 2013), a class of insulin sensitizing drugs, and as a regulator of insulin secretion (Patterson et al., 2014; Vigueira et al., 2014);”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Colca et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Interplay between lipids and branched-chain amino acids in development of insulin resistance
Newgard, C. B. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.01.024 · Cited by 1,080
Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5
Choi, J. H., Banks, A. S., Estall, J. L., Kajimura, S., Boström, P., Laznik, D., Ruas, J. L., Chalmers, M. J., Kamenecka, T. M., Blüher, M., et al. (2010) · Nature · doi:10.1038/nature09291 · Cited by 897
A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila , and Humans
Bricker, D. K., Taylor, E. B., Schell, J. C., Orsak, T., Boutron, A., Chen, Y.-C., Cox, J. E., Cardon, C. M., Van Vranken, J. G., Dephoure, N., et al. (2012) · Science · doi:10.1126/science.1218099 · Cited by 843
Identification and Functional Expression of the Mitochondrial Pyruvate Carrier
Herzig, S., Raemy, E., Montessuit, S., Veuthey, J.-L., Zamboni, N., Westermann, B., Kunji, E. R. S., & Martinou, J.-C. (2012) · Science · doi:10.1126/science.1218530 · Cited by 747
Sunny, N. E., Parks, E. J., Browning, J. D., & Burgess, S. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.004 · Cited by 672
A high-sugar diet produces obesity and insulin resistance in wild-type Drosophila
Musselman, L. P., Fink, J. L., Narzinski, K., Ramachandran, P. V., Hathiramani, S. S., Cagan, R. L., & Baranski, T. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.007948 · Cited by 564
Kusminski, C. M., Holland, W. L., Sun, K., Park, J., Spurgin, S. B., Lin, Y., Askew, G. R., Simcox, J., McClain, D. A., Li, C., et al. (2012) · Nature Medicine · doi:10.1038/nm.2899 · Cited by 474
Satapati, S., Sunny, N. E., Kucejova, B., Fu, X., He, T. T., Méndez-Lucas, A., Shelton, J. M., Perales, J. C., Browning, J. D., & Burgess, S. C. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m023382 · Cited by 407 · cited 1×
“have shown that over activation of the TCA cycle is part of the pathology associated with over nutrition and hepatic insulin resistance [27] and this may also contribute to non-alcoholic fatty liver disease [28].”
BackgroundColca, J. R., McDonald, W. G., Waldon, D. J., Leone, J. W., Lull, J. M., Bannow, C. A., Lund, E. T., & Mathews, W. R. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00424.2003 · Cited by 342
Self-citation
Cited by
Sorted by citations
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes
Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 520
Self-citationCurrent and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Rotman, Y., & Sanyal, A. J. (2016) · Gut · doi:10.1136/gutjnl-2016-312431 · Cited by 420
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 390
Schell, J. C., Olson, K. A., Jiang, L., Hawkins, A. J., Van Vranken, J. G., Xie, J., Egnatchik, R. A., Earl, E. G., DeBerardinis, R. J., & Rutter, J. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.026 · Cited by 363
Photoaffinity Labeling in Target- and Binding-Site Identification
Smith, E. M., & Collins, I. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.152 · Cited by 371
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes‐McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 373
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D. S., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 340
Sunny, N. E., Bril, F., & Cusi, K. J. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.11.006 · Cited by 327
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier
Divakaruni, A. S., Wiley, S. E., Rogers, G. W., Andreyev, A. Y., Petrosyan, S., Loviscach, M., Wall, E. A., Yadava, N., Heuck, A. P., Ferrick, D. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303360110 · Cited by 308
Self-citationMorley, L. C., Tang, T., Yasmin, E., Norman, R. J., & Balen, A. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub6 · Cited by 296
Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier
Vacanti, N. M., Divakaruni, A. S., Green, C. R., Parker, S. J., Henry, R. R., Ciaraldi, T. P., Murphy, A. N., & Metallo, C. M. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.024 · Cited by 277
Self-citationThe ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D. S., & Foltynie, T. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 280
Mitochondrial pyruvate transport: a historical perspective and future research directions
McCommis, K. S., & Finck, B. N. (2015) · Biochemical Journal · doi:10.1042/bj20141171 · Cited by 277
Self-citationImmunological mechanisms and therapeutic targets of fatty liver diseases
Wang, H., Mehal, W. Z., Nagy, L. E., & Rotman, Y. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00579-3 · Cited by 234
McCommis, K. S., Chen, Z., Fu, X., McDonald, W. G., Colca, J. R., Kletzien, R. F., Burgess, S. C., & Finck, B. N. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.07.028 · Cited by 211
Self-citationHarrison, S. A., Alkhouri, N., Davison, B. A., Sanyal, A., Edwards, C., Colca, J. R., Lee, B. H., Loomba, R., Cusi, K., Kolterman, O., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.023 · Cited by 211
Self-citationAdipose Tissue as an Endocrine Organ
McGown, C., Birerdinc, A., & Younossi, Z. M. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.012 · Cited by 200
A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
Skat‐Rørdam, J., Ipsen, D. H., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13190 · Cited by 197
Ghosh, A., Tyson, T., George, S., Hildebrandt, E. N., Steiner, J. A., Madaj, Z., Schulz, E., Machiela, E., McDonald, W. G., Galvis, M. L. E., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2210 · Cited by 193
Self-citationZheng, Y., Wang, S., Wu, J., & Wang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04367-1 · Cited by 197
Gao, R., Li, Y., Xu, Z., Zhang, F., Xu, J., Hu, Y., Yin, J., Yang, K., Sun, L., Wang, Q., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000279 · Cited by 184
Hallmarks of a new era in mitochondrial biochemistryPreprint
Pagliarini, D. J., & Rutter, J. P. (2013) · Genes & Development · doi:10.1101/gad.229724.113 · Cited by 184
Regulation of Tumor Initiation by the Mitochondrial Pyruvate Carrier
Bensard, C., Wisidagama, D. R., Olson, K. A., Berg, J. A., Krah, N. M., Schell, J. C., Nowinski, S. M., Fogarty, S., Bott, A. J., Wei, P., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.002 · Cited by 170
Yin, Y., Choi, S., Xu, Z., Zeumer, L., Kanda, N., Croker, B. P., & Morel, L. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501537 · Cited by 171
Minireview: Challenges and Opportunities in Development of PPAR Agonists
Wright, M. B., Bortolini, M., Tadayyon, M., & Bopst, M. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1427 · Cited by 172
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Metabolic Targets in Nonalcoholic Fatty Liver Disease
Esler, W. P., & Bence, K. K. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.007 · Cited by 145
PPARγ is a nexus controlling alternative activation of macrophages via glutamine metabolismPreprint
Nelson, V. L., Nguyen, H. C. B., García‐Cañaveras, J. C., Briggs, E. R., Ho, W. Y., DiSpirito, J. R., Marinis, J. M., Hill, D. A., & Lazar, M. A. (2018) · Genes & Development · doi:10.1101/gad.312355.118 · Cited by 147
McCommis, K. S., Hodges, W. T., Brunt, E. M., Nalbantoglu, I., McDonald, W. G., Holley, C. L., Fujiwara, H., Schaffer, J. E., Colca, J. R., & Finck, B. N. (2016) · Hepatology · doi:10.1002/hep.29025 · Cited by 139
Self-citationMetformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome
Sharpe, A., Morley, L. C., Tang, T. H., Norman, R. J., & Balen, A. H. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013505 · Cited by 141
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Ciaula, A. D., Passarella, S., Shanmugam, H., Noviello, M., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105375 · Cited by 142
Breakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Ferecatu, I., Gonçalves, S., Golinelli‐Cohen, M., Clémancey, M., Martelli, A., Riquier, S., Guittet, É., Latour, J., Puccio, H. M., Drapier, J., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.548438 · Cited by 125
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 126
Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis
Finck, B. N. (2018) · Diabetes · doi:10.2337/dbi18-0024 · Cited by 125
Self-citationThe mitochondrial pyruvate carrier in health and disease: To carry or not to carry?
Bender, T., & Martinou, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.01.017 · Cited by 122
Recent Advances in Target Characterization and Identification by Photoaffinity Probes
Sumranjit, J., & Chung, S. (2013) · Molecules · doi:10.3390/molecules180910425 · Cited by 116
PPARs modulate cardiac metabolism and mitochondrial function in diabetes
Lee, T., Bai, K., Lee, T.-I., Chao, T., Kao, Y., & Chen, Y. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-016-0309-5 · Cited by 116
Precision pharmacology for Alzheimer’s disease
Hampel, H. J., Vergallo, A., Aguilar, L. F., Benda, N., Broich, K., Cuello, A. C., Cummings, J. L., Dubois, B., Federoff, H. J., Fiandaca, M. S., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.014 · Cited by 114
Lee, M. A., Tan, L., Yang, H., Im, Y.-G., & Im, Y. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-17082-x · Cited by 111
mitoNEET as a novel drug target for mitochondrial dysfunction
Geldenhuys, W. J., Leeper, T. C., & Carroll, R. T. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.05.001 · Cited by 108
Vigueira, P. A., McCommis, K. S., Schweitzer, G. G., Remedi, M. S., Chambers, K. T., Fu, X., McDonald, W. G., Cole, S. L., Colca, J. R., Kletzien, R. F., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.017 · Cited by 103
Self-citationDu, J., Cleghorn, W. M., Contreras, L., Lindsay, K. J., Rountree, A. M., Chertov, A. O., Turner, S. J., Sahaboglu, A., Linton, J., Sadı́lek, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.507285 · Cited by 86
Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer
Colca, J. R., VanderLugt, J. T., Adams, W. J., Shashlo, A., McDonald, W. G., Liang, J., Zhou, R., & Orloff, D. G. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.10 · Cited by 85
Self-citationMitochondrial pyruvate import and its effects on homeostasis
Vanderperre, B., Bender, T., Kunji, E. R. S., & Martinou, J. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.10.008 · Cited by 83
MitoNEET-dependent formation of intermitochondrial junctions
Vernay, A., Marchetti, A., Sabra, A., Jauslin, T. N., Rosselin, M., Scherer, P. E., Demaurex, N., Orci, L., & Cosson, P. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706643114 · Cited by 81
Rauckhorst, A. J., Gray, L. R., Sheldon, R. D., Fu, X., Pewa, A. D., Feddersen, C. R., Dupuy, A. J., Gibson-Corley, K. N., Cox, J. E., Burgess, S. C., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.002 · Cited by 74
Quansah, E., Peelaerts, W., Langston, J. W., Simon, D. K., Colca, J. R., & Brundin, P. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0260-x · Cited by 76
Self-citationDesigning Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology
Borsari, C., Trader, D. J., Tait, A., & Costi, M. P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01456 · Cited by 76
The yeast mitochondrial pyruvate carrier is a hetero-dimer in its functional state
Tavoulari, S., Thangaratnarajah, C., Mavridou, V., Harbour, M. E., Martinou, J., & Kunji, E. R. (2019) · The EMBO Journal · doi:10.15252/embj.2018100785 · Cited by 73
Li, X., Han, G., Li, X., Kan, Q., Fan, Z., Li, Y., Ji, Y., Zhao, J., Zhang, M., Grigalavicius, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18199 · Cited by 78
Regulation of pyruvate metabolism in metabolic-related diseases
Jeoung, N. H., Harris, C. R., & Harris, R. A. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9284-2 · Cited by 68
Yaribeygi, H., Atkin, S. L., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27754 · Cited by 72
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00352 · Cited by 68
The mitochondrial pyruvate carrier at the crossroads of intermediary metabolism
Yiew, N. K. H., & Finck, B. N. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00074.2022 · Cited by 64
Self-citationVanderperre, B., Herzig, S., Krznar, P., Hörl, M., Ammar, Z., Montessuit, S., Pierredon, S., Zamboni, N., & Martinou, J. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006056 · Cited by 67
Colca, J. R., Tanis, S. P., McDonald, W. G., & Kletzien, R. F. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.839659 · Cited by 61
Self-citationMorris, O., Deng, H., Tam, C., & Jasper, H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108423 · Cited by 59
Mitochondrial pyruvate carrier function and cancer metabolism
Rauckhorst, A. J., & Taylor, E. B. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.05.003 · Cited by 59
Shah, R. C., Matthews, D. C., Andrews, R. D., Capuano, A. W., Fleischman, D. A., VanderLugt, J. T., & Colca, J. R. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666140616113406 · Cited by 58
Self-citationWang, Q. A., Zhang, F., Jiang, L., Ye, R., An, Y., Shao, M., Tao, C., Gupta, R. K., & Scherer, P. E. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00677-17 · Cited by 55
Brust, R., Lin, H., Fuhrmann, J., Asteian, A., Kamenecka, T. M., & Kojetin, D. J. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01015 · Cited by 55
Human mitochondrial pyruvate carrier 2 as an autonomous membrane transporter
Nagampalli, R. S. K., Quesñay, J. E. N., Adamóski, D., Islam, Z., Birch, J., Sebinelli, H. G., Girard, R. M. B. M., Ascenção, C. F. R., Fala, A. M., Pauletti, B. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21740-z · Cited by 53
Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease
Steensels, S., Qiao, J., & Ersoy, B. A. (2020) · Metabolites · doi:10.3390/metabo10070283 · Cited by 53
MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis
Colca, J. R., McDonald, W. G., & Adams, W. J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1494153 · Cited by 49
Self-citationAn ancestral role for the mitochondrial pyruvate carrier in glucose-stimulated insulin secretion
McCommis, K. S., Hodges, W. T., Bricker, D. K., Wisidagama, D. R., Compan, V., Remedi, M. S., Thummel, C. S., & Finck, B. N. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.016 · Cited by 44
Self-citationPyruvate metabolism controls chromatin remodeling during CD4+ T cell activation
Mocholí, E., Russo, L., Gopal, K., Ramstead, A. G., Hochrein, S. M., Vos, H. R., Geeven, G., Adegoke, A., Hoekstra, A. T., van Es, R. M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112583 · Cited by 44
Foltynie, T., & Athauda, D. S. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.008 · Cited by 46
Tavoulari, S., Sichrovsky, M., & Kunji, E. R. S. (2023) · Acta Physiologica · doi:10.1111/apha.14016 · Cited by 45
Diabetic silkworms for evaluation of therapeutically effective drugs against type II diabetes
Matsumoto, Y., Ishii, M., Hayashi, Y., Miyazaki, S., Sugita, T., Sumiya, E., & Sekimizu, K. (2015) · Scientific Reports · doi:10.1038/srep10722 · Cited by 42
Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism
McCommis, K. S., & Finck, B. N. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.09.017 · Cited by 39
Self-citationKey features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer
Tavoulari, S., Schirris, T. J. J., Mavridou, V., Thangaratnarajah, C., King, M. S., Jones, D. T. D., Ding, S., Fearnley, I. M., & Kunji, E. R. S. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101469 · Cited by 38
Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes
Shannon, C. E., Daniele, G., Galindo, C., Abdul-Ghani, M. A., DeFronzo, R. A., & Norton, L. (2016) · FEBS Journal · doi:10.1111/febs.13992 · Cited by 36
Colca, J. R., & Scherer, P. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101409 · Cited by 39
Self-citationMitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice
Hodges, W. T., Jarasvaraparn, C., Ferguson, D., Griffett, K., Gill, L. E., Chen, Y., Ilagan, M. X. G., Hegazy, L., Elgendy, B., Cho, K., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101554 · Cited by 38
Self-citationThe TZD insulin sensitizer clue provides a new route into diabetes drug discovery
Colca, J. R. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1100164 · Cited by 37
Self-citationTulloch, L. B., Menzies, S. K., Fraser, A. L., Gould, E., King, E. F. B., Zacharova, M. K., Florence, G. J., & Smith, T. (2017) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0005886 · Cited by 35
Beňová, A., Ferenčáková, M., Bardová, K., Funda, J., Procházka, J., Špoutil, F., Čajka, T., Dzubanova, M., Balcaen, T., Kerckhofs, G., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101598 · Cited by 35
Characterization of Genomic Vitamin D Receptor Binding Sites through Chromatin Looping and Opening
Seuter, S., Neme, A., & Carlberg, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096184 · Cited by 34
Structure of mitochondrial pyruvate carrier and its inhibition mechanism
Zheng, H., Zhang, J., Xu, Y., Fine, E. J., Suomivuori, C., Dror, R. O., & Feng, L. (2025) · Nature · doi:10.1038/s41586-025-08667-y · Cited by 34
Immune Cell Metabolism in Systemic Lupus Erythematosus
Choi, S., Titov, A. A., Sivakumar, R., Li, W., & Morel, L. M. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0615-7 · Cited by 32
Kamm, D. R., Pyles, K. D., Sharpe, M. C., Healy, L. N., Colca, J. R., & McCommis, K. S. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100807 · Cited by 32
Self-citationMitochondrial target of thiazolidinediones
Colca, J. R., McDonald, W. G., & Kletzien, R. F. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12308 · Cited by 32
Self-citationYiew, N. K. H., Vazquez, J. H., Martino, M. R., Kennon‐McGill, S., Price, J. R., Allard, F. D., Yee, E. U., Layman, A. J., James, L. P., McCommis, K. S., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101808 · Cited by 32
Self-citationPower2: The power of yeast genetics applied to the powerhouse of the cell
Rutter, J. P., & Hughes, A. L. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.12.002 · Cited by 30
Rohatgi, N., Aly, H., Marshall, C. A., McDonald, W. G., Kletzien, R. F., Colca, J. R., & McDaniel, M. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062012 · Cited by 30
Self-citationDiscovery of Novel Insulin Sensitizers: Promising Approaches and Targets
Chen, Y., Ma, H., Dasheng, Z., Zhao, G., Wang, L., Fu, X., & Chen, W. (2017) · PPAR Research · doi:10.1155/2017/8360919 · Cited by 29
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
Jeong, S. W. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0115 · Cited by 29
Mitochondrial drug targets in neurodegenerative diseases
Lee, J. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.11.032 · Cited by 26
Hyperglycemia-Induced Endothelial Dysfunction
Gerő, D. (2018) · InTech eBooks · doi:10.5772/intechopen.71433 · Cited by 33
Grattagliano, I., Ciaula, A. D., Baj, J., Molina‐Molina, E., Shanmugam, H., Garruti, G., Wang, D. Q. ‐., & Portincasa, P. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1433-4_12 · Cited by 28
Treating fatty liver disease by modulating mitochondrial pyruvate metabolism
Colca, J. R., McDonald, W. G., McCommis, K. S., & Finck, B. N. (2017) · Hepatology Communications · doi:10.1002/hep4.1036 · Cited by 23
Self-citationCharacterization of drug-induced human mitochondrial ADP/ATP carrier inhibition
Baron, S. J., King, M. S., Kunji, E. R. S., & Schirris, T. J. J. (2021) · Theranostics · doi:10.7150/thno.54936 · Cited by 23
Identification of protein binding partners of small molecules using label-free methods
Saxena, C. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1227316 · Cited by 22
Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease
Han, S.-H., & Mook‐Jung, I. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.7.893 · Cited by 23
Li, X., Li, Y., Han, G., Li, X., Ji, Y., Fan, Z., Zhong, Y., Cao, J., Zhao, J., Goscinski, M. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13210 · Cited by 23
Bardová, K., Funda, J., Pohl, R., Čajka, T., Hensler, M., Kuda, O., Janovská, P., Adamcová, K., Irodenko, I., Lenkova, L., et al. (2020) · Nutrients · doi:10.3390/nu12123737 · Cited by 24
Self-citation
Metadata
- Authors
- Colca, J. R., McDonald, W. G., Cavey, G. S., Cole, S. L., Holewa, D. D., Brightwell-Conrad, A. S., Wolfe, C. L., Wheeler, J. S., Coulter, K. R., Kilkuskie, P. M., Gracheva, E., Korshunova, Y., Trusgnich, M., Karr, R., Wiley, S. E., Divakaruni, A. S., Murphy, A. N., Vigueira, P. A., Finck, B. N., & Kletzien, R. F.
- Affiliations
- Metabolic Solutions Development Company (United States) (US)
- University of California San Diego (US)
- Washington University in St. Louis (US)
- Corresponding author
- Colca, Jerry R.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-15
- Volume
- 8
- Issue
- 5
- Pages
- e61551
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3655167
- OpenAlex
- W2165311378
- Cited by
- 171
- References
- 30
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 9 · 2023: 12 · 2022: 14 · 2021: 12 · 2020: 14 · 2019: 13 · 2018: 15 · 2017: 20 · 2016: 17 · 2015: 8 · 2014: 17 · 2013: 9
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Michigan Economic Development Corporation
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (AA21228, R42AA021228)
- National Institute of Diabetes and Digestive and Kidney Diseases (R41DK084596, DK081298, DK84596, R42DK081298)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- thiazolidinediones, insulin sensitizers, mitochondrial pyruvate carrier, MPC1, MPC2, pyruvate transport, acetyl-CoA biosynthesis, brown adipose tissue, hemolymph glucose, Drosophila melanogaster, drug target identification
- MeSH terms
- Insulin Secretion, Amino Acid Sequence, Animals, Adipose Tissue, Brown, Drosophila melanogaster, Humans, Hypoglycemic Agents, Insulin, Mitochondria, Molecular Sequence Data, Sequence Homology, Amino Acid, Membrane Transport Proteins, Monocarboxylic Acid Transporters, Mitochondrial Membrane Transport Proteins, Thiazolidinediones, Gene Knockdown Techniques, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review